BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

843 related articles for article (PubMed ID: 28179279)

  • 1. Role of RUNX1 in hematological malignancies.
    Sood R; Kamikubo Y; Liu P
    Blood; 2017 Apr; 129(15):2070-2082. PubMed ID: 28179279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Clinical, Molecular, and Mechanistic Basis of RUNX1 Mutations Identified in Hematological Malignancies.
    Yokota A; Huo L; Lan F; Wu J; Huang G
    Mol Cells; 2020 Feb; 43(2):145-152. PubMed ID: 31964134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic compensation of RUNX family transcription factors in leukemia.
    Kamikubo Y
    Cancer Sci; 2018 Aug; 109(8):2358-2363. PubMed ID: 29883054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RUNX1 and CBFβ Mutations and Activities of Their Wild-Type Alleles in AML.
    Hyde RK; Liu P; Friedman AD
    Adv Exp Med Biol; 2017; 962():265-282. PubMed ID: 28299663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematopoietic stem cells acquire survival advantage by loss of RUNX1 methylation identified in familial leukemia.
    Matsumura T; Nakamura-Ishizu A; Muddineni SSNA; Tan DQ; Wang CQ; Tokunaga K; Tirado-Magallanes R; Sian S; Benoukraf T; Okuda T; Asou N; Matsuoka M; Osato M; Suda T
    Blood; 2020 Oct; 136(17):1919-1932. PubMed ID: 32573733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.
    Tsai SC; Shih LY; Liang ST; Huang YJ; Kuo MC; Huang CF; Shih YS; Lin TH; Chiu MC; Liang DC
    Clin Cancer Res; 2015 Aug; 21(15):3541-51. PubMed ID: 25840971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.
    Metzeler KH; Bloomfield CD
    Adv Exp Med Biol; 2017; 962():175-199. PubMed ID: 28299658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making.
    Mangan JK; Speck NA
    Crit Rev Oncog; 2011; 16(1-2):77-91. PubMed ID: 22150309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Runx transcription factors in the development and function of the definitive hematopoietic system.
    de Bruijn M; Dzierzak E
    Blood; 2017 Apr; 129(15):2061-2069. PubMed ID: 28179276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.
    Harada Y; Harada H
    J Cell Biochem; 2011 Feb; 112(2):425-32. PubMed ID: 21268063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Core binding factor genes and human leukemia.
    Hart SM; Foroni L
    Haematologica; 2002 Dec; 87(12):1307-23. PubMed ID: 12495904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Familial platelet disorder with propensity to acute myelogenous leukemia: genetic heterogeneity and progression to leukemia via acquisition of clonal chromosome anomalies.
    Minelli A; Maserati E; Rossi G; Bernardo ME; De Stefano P; Cecchini MP; Valli R; Albano V; Pierani P; Leszl A; Sainati L; Lo Curto F; Danesino C; Locatelli F; Pasquali F
    Genes Chromosomes Cancer; 2004 Jul; 40(3):165-71. PubMed ID: 15138996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RUNX1 deficiency (familial platelet disorder with predisposition to myeloid leukemia, FPDMM).
    Schlegelberger B; Heller PG
    Semin Hematol; 2017 Apr; 54(2):75-80. PubMed ID: 28637620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Runx1 deficiency predisposes mice to T-lymphoblastic lymphoma.
    Kundu M; Compton S; Garrett-Beal L; Stacy T; Starost MF; Eckhaus M; Speck NA; Liu PP
    Blood; 2005 Nov; 106(10):3621-4. PubMed ID: 16051740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation.
    Wang K; Zhou F; Cai X; Chao H; Zhang R; Chen S
    Hematology; 2020 Dec; 25(1):211-218. PubMed ID: 32476595
    [No Abstract]   [Full Text] [Related]  

  • 16. RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes.
    Koh CP; Wang CQ; Ng CE; Ito Y; Araki M; Tergaonkar V; Huang G; Osato M
    Leukemia; 2013 Sep; 27(9):1793-802. PubMed ID: 23817177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation.
    Kanagal-Shamanna R; Loghavi S; DiNardo CD; Medeiros LJ; Garcia-Manero G; Jabbour E; Routbort MJ; Luthra R; Bueso-Ramos CE; Khoury JD
    Haematologica; 2017 Oct; 102(10):1661-1670. PubMed ID: 28659335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New mechanisms of AML1 gene alteration in hematological malignancies.
    Roumier C; Fenaux P; Lafage M; Imbert M; Eclache V; Preudhomme C
    Leukemia; 2003 Jan; 17(1):9-16. PubMed ID: 12529654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia.
    Bera R; Chiu MC; Huang YJ; Lin TH; Kuo MC; Shih LY
    J Hematol Oncol; 2019 Oct; 12(1):104. PubMed ID: 31640815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Transcription factor RUNX1].
    Markova EN; Petrova NV; Razin SV; Kantidze OL
    Mol Biol (Mosk); 2012; 46(6):846-59. PubMed ID: 23350231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.